

**RUBRA MEDICAMENTS LIMITED**

Statement of Standalone Unaudited Financial Results for the quarter and Half year ended September 30, 2018

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		30-Sep-2018	30-Jun-2018	30-Sep-2017	30-Sep-2018	30-Sep-2017	31-Mar-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	9.09	9.09	103.42	18.18	195.72	229.80
II	Other Income	0.00	0.00	9.28	0.00	15.98	15.98
III	<b>Total Income (I + II)</b>	<b>9.09</b>	<b>9.09</b>	<b>112.70</b>	<b>18.18</b>	<b>211.70</b>	<b>245.78</b>
IV	<b>Expenses:</b>						
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	101.70
	Purchases of Stock in Trade	9.00	9.00	101.53	18.00	188.47	86.94
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	2.45	1.38	3.08	3.83	3.40	12.96
	Finance Costs	0	0.01	0.00	0.01	0.00	0.00
	Depreciation & amortisation expense	0.01	0.01	0.01	0.02	0.02	0.04
	Other Expenses	2.60	0.74	5.05	3.34	11.71	31.69
	<b>Total Expenses (IV)</b>	<b>14.06</b>	<b>11.14</b>	<b>109.67</b>	<b>25.20</b>	<b>203.60</b>	<b>233.33</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>-4.97</b>	<b>-2.05</b>	<b>3.03</b>	<b>-7.02</b>	<b>8.10</b>	<b>12.45</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	28.82
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>-4.97</b>	<b>-2.05</b>	<b>3.03</b>	<b>-7.02</b>	<b>8.10</b>	<b>-16.37</b>
VIII	<b>Tax Expense:</b>						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-4.97</b>	<b>-2.05</b>	<b>3.03</b>	<b>-7.02</b>	<b>8.10</b>	<b>-16.37</b>
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Profit/(loss) from Discontinuing operations (after tax)(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>-4.97</b>	<b>-2.05</b>	<b>3.03</b>	<b>-7.02</b>	<b>8.10</b>	<b>-16.37</b>
XIII	Other comprehensive income						
XIV	A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>-4.97</b>	<b>-2.05</b>	<b>3.03</b>	<b>-7.02</b>	<b>8.10</b>	<b>-16.37</b>
XVI	Earnings per equity share (for continuing operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.06 0.06	0.00 0.00	0.15 0.15	0.00 0.00
XVII	Earnings per equity share (for discontinued operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
XVIII	Earnings per equity share (for discontinued & continuing operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.06 0.06	0.00 0.00	0.15 0.15	0.00 0.00
	<b>NOTES:</b>						
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
2	The Segment - wise details are not applicable to the Company as the Company has no segments.						
3	The results are Ind-AS compliant however, the previous year figures are not subject to limited review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.						
4	The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Rubra Medicaments Limited

Place: Mumbai

Date: November 12, 2018

Abha Kapoor  
Director (Finance) & CFO  
DIN-02799429

**RUBRA MEDICAMENTS LIMITED**

(Rs. in Lakhs)

STATEMENT OF ASSETS AND LIABILITIES			
	Particulars	Figures as at the end of current reporting period	
		September 30, 2018	
		Unaudited	Audited
	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	0.03	0.05
	(b) Capital work-in-progress		-
	(c) Investment property		-
	(d) Goodwill		-
	(e) Other intangible assets		-
	(f) Intangible assets under development		-
	(g) Biological assets other than bearer plants		-
	(h) Financial Assets		
	(i) Investments		-
	(ii) Trade receivables		-
	(iii) Loans		-
	(iv) Others (to be specified) - Advances		-
	(i) Deferred tax assets (net)		-
	(j) Other non-current assets	1.77	1.77
	<b>Total non-current assets</b>	<b>1.80</b>	<b>1.82</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories		-
	(b) Financial Assets		
	(i) Investments		-
	(ii) Trade receivables	20.44	34.37
	(iii) Cash and cash equivalents	23.91	29.74
	(iv) Bank balances other than (iii) above	5.99	3.89
	(v) Loans	34.80	11.50
	(vi) Others to be specified - Advances		-
	(c) Current tax assets (net)		-
	(d) Other current assets		-
	<b>Total current assets</b>	<b>85.14</b>	<b>79.50</b>
	<b>Total assets</b>	<b>86.94</b>	<b>81.32</b>
<b>1</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-494.67	-487.64
	<b>Total equity</b>	<b>52.16</b>	<b>59.19</b>
	<b>LIABILITIES</b>		
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings		-
	(ii) Trade payables		-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)		-
	(b) Provisions		-
	(c) Deferred tax liabilities (net)	0.01	0.01
	(d) Other non-current liabilities		-
	<b>Total non-current liabilities</b>	<b>0.01</b>	<b>0.01</b>
	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings		-
	(ii) Trade payables	30.87	16.57
	(iii) Other financial liabilities (other than those specified in item (a))		-
	(b) Other current liabilities		-
	(c) Provisions, current	3.90	5.55
	(d) Current tax liabilities (Net)		-
	<b>Total current liabilities</b>	<b>34.77</b>	<b>22.12</b>
	<b>Total liabilities</b>	<b>34.78</b>	<b>22.13</b>
	<b>Total Equity and Liabilities</b>	<b>86.94</b>	<b>81.32</b>